{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:24:50Z","timestamp":1785770690103,"version":"3.56.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Studies interrogating therapeutics which alter the excitation-inhibition balance in the treatment of autism spectrum disorder (ASD) have reported mixed results on social and behavioral outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The aim of this randomized, double-blind placebo-controlled pilot trial was to evaluate neurocognitive effects of memantine over a 24-week trial. Twenty-three children ages 6\u201312 years old with ASD were randomized to memantine or placebo. Primary outcomes included measures of apraxia and expressive language with evaluations at midpoint (week 12) and endpoint (week 24). Secondary outcomes included memory and adaptive behavior measures. Exploratory outcomes included changes in overall cognitive functioning and behavior (e.g., Aberrant Behavior Checklist).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Results suggest that memantine was well-tolerated. Dropout rates were high across groups with only 14 participants completing the 6-month trial. Memantine was not associated with improvements in apraxia and expressive language. Treatment with memantine was associated with improvements in verbal recognition memory as measured by the Narrative Memory-Recognition (NEPSY-II) (\n                      <jats:italic toggle=\"yes\">F<\/jats:italic>\n                      \u2009=\u20095.05,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.03). In addition, exploratory analyses of changes in Intelligence quotient (IQ) suggest improvements on verbal IQ (\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      \u2009=\u20091.8).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Results suggest future studies of memantine in ASD may benefit from shifting treatment targets from social and behavioral outcomes to exploration of effects of memantine on cognition, potentially as an adjunct to learning and educational interventions.\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:uri>\n                      : NCT01372449.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2021.0010","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T16:57:21Z","timestamp":1632157041000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-4533","authenticated-orcid":false,"given":"Latha Valluripalli","family":"Soorya","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Fogg","sequence":"additional","affiliation":[{"name":"Department of Nursing, Rush University Medical Center, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Ocampo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Printen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Youngkin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Halpern","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kolevzon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grodberg","sequence":"additional","affiliation":[{"name":"Child Study Center, Yale University, New Haven, Connecticut, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokia","family":"Anagnostou","sequence":"additional","affiliation":[{"name":"Holland Bloorview Children's Rehabilitation Hospital, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022238706604"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0146"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03629.x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1996.tb01241.x"},{"key":"e_1_3_4_6_1","first-page":"280","article-title":"Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome","volume":"4","author":"Berry-Kravis EM","year":"2017","unstructured":"Berry-Kravis EM, , Lindemann L, , J\u00f8nch AE, , Apostol G, , Bear MF, , Carpenter RL, , Crawley JN, , Curie A, , DesPortes V, , Hossain F, , Gasparini F, , Gomez-Mancilla B, , Hessi D, , Loth E, , Scharf SH, , Wang PP, , VonRaison F, , Hagerman R, , Spooren W, , Jacquemont S: Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome. Nat Rev Drug Discov, 4:280\u2013299, 2017.","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054714538656"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-4133"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09582"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807302611"},{"key":"e_1_3_4_11_1","unstructured":"Constantino JN: Social Responsiveness Scale (SRS). Los Angeles CA Western Psychological Services 2005."},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","unstructured":"Dunn W: The Sensory Profile. San Antonio TX The Psychological Corporation 1999.","DOI":"10.1037\/t15155-000"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0034"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0518-9"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3022-z"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Gioia GA Isquith PK Guy SC Kenworthy L: Behavior Rating Inventory of Executive Function Professional Manual. Psychological Assessment Resources (PAR) Odessa FL 2000.","DOI":"10.1037\/t73087-000"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12892"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000142668.29191.13"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1362361318824103"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","unstructured":"Hickman LA: The Apraxia Profile: A Descriptive Assessment Tool for Children. San Antonio TX Communication Skill Builders 1997.","DOI":"10.1037\/t14969-000"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000499"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_100_18"},{"key":"e_1_3_4_23_1","first-page":"175","article-title":"NEPSY\u2014Second Edition (NEPSY-II)","volume":"28","author":"Korkman M","year":"2007","unstructured":"Korkman M, , Kirk U, , Kemp S: NEPSY\u2014Second Edition (NEPSY-II). Harcourt Assess J Psychoeduc Assess, 28:175\u2013182, 2007.","journal-title":"Harcourt Assess J Psychoeduc Assess"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.10.007"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.05.011"},{"key":"e_1_3_4_26_1","first-page":"7","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"9","author":"Lemonnier E","year":"2017","unstructured":"Lemonnier E, , Villeneuve N, , Sonie S, , Serret S, , Rosier A, , Rou M, , Brosset P, , Viellard M, , Bernoux D, , Rondeau S, , Thummler S, , Ravel D, , Ben-Ari Y: Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry, 9:7, 2017.","journal-title":"Transl Psychiatry"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Lord C Rutter M DiLavore P Risi S: Autism diagnostic observation schedule (ADOS). Los Angeles CA Western Psychological Services 1999.","DOI":"10.1037\/t17256-000"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02172145"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/104012371803000307"},{"key":"e_1_3_4_30_1","first-page":"1","article-title":"Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: A systematic review of the literature","author":"Mechler K","year":"2017","unstructured":"Mechler K, , H\u00e4ge A, , Schweinfurth Glennon JC, , Dijkhuizen RM, , Murphy D, , Durston S, , Williams S, , Buitelaar JK, , Banaschewski T, , Dittmann RW: Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: A systematic review of the literature. Jugendpsychiatrie und Psychotherapie [Adolesc Psychiatry Psychother] , 1\u201318, 2017.","journal-title":"Jugendpsychiatrie und Psychotherapie [Adolesc Psychiatry Psychother]"},{"key":"e_1_3_4_31_1","first-page":"113","article-title":"Plasma excitatory amino acids in autism","volume":"37","author":"Moreno-Fuenmayor H","year":"1996","unstructured":"Moreno-Fuenmayor H, , Borjas L, , Arrieta A, , Valera V, , Socorro-Candanoza L: Plasma excitatory amino acids in autism. Investigaci\u00f3n Cl\u00ednica [Clin Res], 37:113\u2013128, 1996.","journal-title":"Investigaci\u00f3n Cl\u00ednica [Clin Res]"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.07.033"},{"key":"e_1_3_4_33_1","first-page":"19","article-title":"Comparing efficacy and side effects of memantine vs","volume":"50","author":"Nikvarz N","year":"2016","unstructured":"Nikvarz N, , Alaghband-rad J, , Tehrani-Doost M, , Alimadadi A, , Ghaeli P: Comparing efficacy and side effects of memantine vs. risperidone in treatment of autistic disorder. Pharmacopsychiatry, 50:19\u201325, 2016.","journal-title":"risperidone in treatment of autistic disorder. Pharmacopsychiatry"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.517"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-013-9398-z"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.9.1618"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013128"},{"key":"e_1_3_4_38_1","unstructured":"Roid GH: Stanford-Binet Intelligence Scales (5th ed.). Itasca IL Riverside 2003."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1993.tb03378.x"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.06.013"},{"key":"e_1_3_4_41_1","doi-asserted-by":"crossref","unstructured":"Sparrow SS Cicchetti D Balla DA: Vineland Adaptive Behavior Scales Second Edition (Vineland-II). APA PsycTests Circle Pines MN 2005.","DOI":"10.1037\/t15164-000"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X113116660046"},{"key":"e_1_3_4_43_1","volume-title":"Wechsler Intelligence Scale for Children","author":"Weschler D","year":"2003","unstructured":"Weschler D: Wechsler Intelligence Scale for Children (4th ed.). The Psychological Corporation, Harcourt Brace & Company, San Antonio, TX, 2003.","edition":"4"},{"key":"e_1_3_4_44_1","doi-asserted-by":"crossref","unstructured":"Wechsler D: Wechsler Abbreviated Scale of Intelligence Second Edition (WASI-II). San Antonio TX NCS Pearson 2011.","DOI":"10.1037\/t15171-000"},{"key":"e_1_3_4_45_1","volume-title":"Expressive Vocabulary Test","author":"Williams KT","year":"2007","unstructured":"Williams KT: Expressive Vocabulary Test (2nd ed.). Circle Pines, MN, AGS Publishing, 2007.","edition":"2"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.122"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep21719"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717001271"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2021.0010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:10Z","timestamp":1777388170000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2021.0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1089\/cap.2021.0010"],"URL":"https:\/\/doi.org\/10.1089\/cap.2021.0010","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}